The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece
…, AF Lambropoulos, M Gueorguiev, S Chrisafi… - Cancer letters, 2005 - Elsevier
The aim of this study was to explore a possible association between p53 codon 72, Her 2
codon 655 and MTHFR C677T polymorphisms and breast cancer in Northern Greece. We …
codon 655 and MTHFR C677T polymorphisms and breast cancer in Northern Greece. We …
[HTML][HTML] Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel
…, H Trihia, V Malamou-Mitsi, S Miliaras, S Chrisafi… - PloS one, 2012 - journals.plos.org
Background The aim of the present study was to investigate the efficacy of adjuvant dose-dense
sequential chemotherapy with epirubicin, paclitaxel, and CMF in subgroups of patients …
sequential chemotherapy with epirubicin, paclitaxel, and CMF in subgroups of patients …
[HTML][HTML] Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer
…, E Pectasides, G Karayannopoulou, S Chrisafi… - Esmo Open, 2019 - Elsevier
Background The clinical relevance of mismatch repair (MMR) status in patients with
nonmetastatic cancer across tumour types remains unclear. Our goal was to investigate the …
nonmetastatic cancer across tumour types remains unclear. Our goal was to investigate the …
Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating …
…, V Kotoula, GA Koliou, K Manousou, S Chrisafi… - Cancer Immunology …, 2020 - Springer
Background Tumor-infiltrating lymphocytes (TILs) and their subsets contribute to breast
cancer prognosis. We investigated the prognostic impact of CD3+, CD8+ and FOXP3+ TILs in …
cancer prognosis. We investigated the prognostic impact of CD3+, CD8+ and FOXP3+ TILs in …
The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping
The Androgen Receptor (AR) is a potential prognostic marker and therapeutic target in
breast cancer. We evaluated AR protein expression in high-risk breast cancer treated in the …
breast cancer. We evaluated AR protein expression in high-risk breast cancer treated in the …
Angiogenic and antiangiogenic VEGFA splice variants in colorectal cancer: prospective retrospective cohort study in patients treated with irinotecan-based …
…, G Papatsibas, I Bombolaki, S Chrisafi… - Clinical Colorectal …, 2019 - Elsevier
Background Alternative splicing of vascular endothelial growth factor A (VEGFA) results in
VEGFAxxxb antiangiogenic isoforms that fail to activate angiogenesis. Bevacizumab, widely …
VEGFAxxxb antiangiogenic isoforms that fail to activate angiogenesis. Bevacizumab, widely …
Detection and typing of human papillomavirus DNA in uterine cervices with coexistent grade I and grade III intraepithelial neoplasia: biologic progression or …
…, D Miliaras, AF Lambropoulos, S Chrisafi… - European Journal of …, 2005 - Elsevier
OBJECTIVE:: To examine the HPV type infection of cervical cone specimens with coexistent
CIN1 and CIN3 lesions, in order to define if coexistence of low- and high-grade lesions in …
CIN1 and CIN3 lesions, in order to define if coexistence of low- and high-grade lesions in …
[HTML][HTML] Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancer
…, K Chatzopoulos, S Lakis, S Chrisafi… - PLoS …, 2018 - journals.plos.org
The aim of this study was to investigate the prognostic value of the Hedgehog (Gli, Patched-1,
Shh, Smo) and Notch (Jag1, Notch2, Notch3) pathway members, in comparison to a panel …
Shh, Smo) and Notch (Jag1, Notch2, Notch3) pathway members, in comparison to a panel …
A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas
…, D Televantou, S Lambaki, S Chrisafi… - Journal of …, 2013 - Springer
We undertook this phase I study to investigate the feasibility of the combination of temozolomide
(TMZ) and lapatinib (LP) and to define the maximum tolerated dose (MTD) of LP in …
(TMZ) and lapatinib (LP) and to define the maximum tolerated dose (MTD) of LP in …
Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays
…, AG Eleftheraki, E Kouvaras, S Chrisafi… - Anticancer …, 2013 - ar.iiarjournals.org
Background: Tissue microarrays (TMAs) are an attractive alternative to analysis of whole
sections (WS). For breast carcinomas, the recent recommendations for cut-offs (ie Ki67, H-score…
sections (WS). For breast carcinomas, the recent recommendations for cut-offs (ie Ki67, H-score…